Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease.
暂无分享,去创建一个
[1] F. van Rhee,et al. Predictors of response to anti‐IL6 monoclonal antibody therapy (siltuximab) in idiopathic multicentric Castleman disease: secondary analyses of phase II clinical trial data , 2018, British journal of haematology.
[2] J. Rossi,et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease. , 2018, Blood.
[3] A. Stonestrom,et al. Plasma proteomics identifies a ‘chemokine storm’ in idiopathic multicentric Castleman disease , 2018, American journal of hematology.
[4] R. Warnke,et al. Next-generation sequencing of idiopathic multicentric and unicentric Castleman disease and follicular dendritic cell sarcomas. , 2018, Blood advances.
[5] L. Vercellino,et al. The full spectrum of Castleman disease: 273 patients studied over 20 years , 2018, British journal of haematology.
[6] Q. Cai,et al. Clinical characteristics and outcomes of Castleman disease: A multicenter study of 185 Chinese patients , 2017, Cancer science.
[7] V. Krymskaya,et al. Prolonged Remission Achieved in a Relapsing Idiopathic Multicentric Castleman Disease Patient with a Novel, Targeted Treatment Approach , 2017 .
[8] Amy Y. Liu,et al. Preliminary Results from Accelerate, an International, Web-Based, Natural History Registry of Castleman Disease , 2017 .
[9] M. Feldman,et al. Virome Capture Sequencing in Castleman Disease Identifies Associations with Herpesviridae Family Members but No Novel Viruses , 2017 .
[10] D. Pinato,et al. Relapse of HHV8-positive multicentric Castleman disease following rituximab-based therapy in HIV-positive patients. , 2017, Blood.
[11] J. Rossi,et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease. , 2017, Blood.
[12] K. Young,et al. Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease. , 2017, Blood.
[13] T. Yoshino,et al. Elevated serum interferon γ-induced protein 10 kDa is associated with TAFRO syndrome , 2017, Scientific Reports.
[14] S. Post,et al. Diagnostic Utility of Interleukin-6 Expression by Immunohistochemistry in Differentiating Castleman Disease Subtypes and Reactive Lymphadenopathies. , 2016, Annals of clinical and laboratory science.
[15] Dermot Kelleher,et al. Idiopathic multicentric Castleman's disease: a systematic literature review. , 2016, The Lancet. Haematology.
[16] Dermot Kelleher,et al. The collaborative network approach: a new framework to accelerate Castleman's disease and other rare disease research. , 2016, The Lancet. Haematology.
[17] T. Yoshino,et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV‐8‐negative multicentric Castleman disease , 2016, American journal of hematology.
[18] W. Lipkin,et al. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and Comprehensive Virome Analysis , 2015, mBio.
[19] R. Kurzrock,et al. A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease , 2015, Oncotarget.
[20] E. K. Egorova,et al. [Clinical and morphological features of different types of Castleman's disease]. , 2015, Terapevticheskii arkhiv.
[21] N. Munshi,et al. Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease , 2015, Clinical Cancer Research.
[22] N. Munshi,et al. Use of a claims database to characterize and estimate the incidence rate for Castleman disease , 2015, Leukemia & lymphoma.
[23] J. Huh,et al. Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience , 2014, Blood research.
[24] J. Rossi,et al. Siltuximab for multicentric Castleman's disease: a randomised, double-blind, placebo-controlled trial. , 2014, The Lancet. Oncology.
[25] M. King,et al. Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.
[26] L. Medeiros,et al. Monoclonality and cytogenetic abnormalities in hyaline vascular Castleman disease , 2014, Modern Pathology.
[27] F. van Rhee,et al. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. , 2014, Blood.
[28] A. Liston,et al. Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.
[29] Y. Lai,et al. [Expression of interleukin-6 and its clinicopathological significance in Castleman's disease]. , 2013, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi.
[30] F. van Rhee,et al. Eruptive cherry hemangiomatosis associated with multicentric Castleman disease: a case report and diagnostic clue. , 2013, JAMA dermatology.
[31] D. Weisenburger,et al. The clinical spectrum of Castleman's disease , 2012, American journal of hematology.
[32] R. West,et al. TdT+ T-lymphoblastic Populations Are Increased in Castleman Disease, in Castleman Disease in Association With Follicular Dendritic Cell Tumors, and in Angioimmunoblastic T-cell Lymphoma , 2012, The American journal of surgical pathology.
[33] R. Yarchoan,et al. Recent advances in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease , 2012, Current opinion in oncology.
[34] I. Vancurova,et al. Bortezomib Induces Nuclear Translocation of IκBα Resulting in Gene-Specific Suppression of NF-κB–Dependent Transcription and Induction of Apoptosis in CTCL , 2011, Molecular Cancer Research.
[35] S. Lonial,et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. , 2010, Journal of Clinical Oncology.
[36] R. Kurzrock,et al. Successful Treatment of Castleman's Disease with Interleukin-1 Receptor Antagonist (Anakinra) , 2010, Molecular Cancer Therapeutics.
[37] I. Touitou,et al. The clinical spectrum of 94 patients carrying a single mutated MEFV allele. , 2009, Rheumatology.
[38] D. Pariente,et al. IL-1RA Agonist (Anakinra) in the Treatment of Multifocal Castleman Disease: Case Report , 2008, Journal of pediatric hematology/oncology.
[39] C. Heussel,et al. Effects of bortezomib on pro‐inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman Disease , 2006, British journal of haematology.
[40] L. Staudt,et al. Clinical Trials and Observations , 2007 .
[41] I. Screpanti,et al. Interleukin-6 and CAAT/enhancer binding protein beta-deficient mice act as tools to dissect the IL-6 signalling pathway and IL-6 regulation. , 1997, Immunobiology.
[42] H. Groen,et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. , 1994, Blood.
[43] C. Nakaseko,et al. [Chromosomal abnormalities in Castleman's disease with high levels of serum interleukin-6]. , 1993, [Rinsho ketsueki] The Japanese journal of clinical hematology.